We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
COVID‐19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey.
- Authors
Matucci, Andrea; Caminati, Marco; Vivarelli, Emanuele; Vianello, Andrea; Micheletto, Claudio; Menzella, Francesco; Crisafulli, Ernesto; Passalacqua, Giovanni; Bagnasco, Diego; Lombardi, Carlo; Parronchi, Paola; Crivellaro, Mariaangiola A.; Chieco‐Bianchi, Fulvia; Rita Marchi, Maria; Guarnieri, Gabriella; Cosmi, Lorenzo; Rossi, Oliviero; Almerigogna, Fabio; Senna, Gianenrico; Vultaggio, Alessandra
- Abstract
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey Keywords: asthma; biologics; infections; virus EN asthma biologics infections virus 871 874 4 03/09/21 20210301 NES 210301 To the Editor, Several reports describe an higher risk for viral infections in patients with asthma.1,2 Novel coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that shows a predilection to infect the lower and upper airway tract, thus creating an higher clinical issue in asthmatic patients.3 Data about the prevalence and severity of COVID-19 in asthma patients are very scarce, and no conclusive evidence is available.4 Additional concerns about the effects of asthma medications on SARS-CoV-2 infection may arise, and data about severe asthma during ongoing biological treatment in COVID-19 pandemic are lacking. The four confirmed COVID-19 cases displayed a good control of asthma symptoms before SARS-CoV-2 infection, without asthma exacerbations during the last 3 months before illness.
- Subjects
COVID-19; BRONCHIECTASIS; SARS-CoV-2; COVID-19 pandemic
- Publication
Allergy, 2021, Vol 76, Issue 3, p871
- ISSN
0105-4538
- Publication type
Article
- DOI
10.1111/all.14516